Deborah L.Cadena Ph.D.

Patent Agent

(T) 1.858.314.1160

Dr. Debbie Cadena focuses her practice on life sciences and biotechnology patent prosecution. She has more than a decade of experience in all aspects of patent prosecution, including drafting and prosecuting U.S. and non-U.S. patent applications, managing patent portfolios, and evaluating competitive technologies.

Debbie frequently counsels clients on strategies for formulating and implementing intellectual property portfolios that optimize business objectives. She is a former post-doctoral fellow and research faculty member in the School of Medicine at the University of California, San Diego and has extensive scientific experience in the areas of biochemistry, molecular biology, and cell biology. Debbie has assisted clients in the realization of patent portfolios in such diverse technology areas as immunology (including vaccines and antibody therapeutics), genomics, proteomics, systems biology, small molecules, medicinal chemistry, peptide and protein chemistry, drug screening, in vivo and ex vivo therapeutics (including production and formulation of biologics, gene therapy, and stem cell therapy), transgenic animals, nutraceuticals, and bioinformatics.

Experience

Celgene acquires Juno Therapeutics for $9 billion
On behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications.

Genomatica establishes global patent portfolios related to production of more sustainable versions of major chemicals, made from alternative feedstocks
Jones Day represents Genomatica in the development of a worldwide patent portfolio related to methods of producing high-volume basic and intermediate chemicals from alternative feedstocks, such as sugars and cellulosic biomass, using engineered microorganisms.

Additional Publications

  • 44 African Countries Sign Agreement to Establish African Continental Free Trade Area
We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.